204 related articles for article (PubMed ID: 30572144)
1. Acute hypercalcemia and excessive bone resorption following anti-RANKL withdrawal: Case report and brief literature review.
Roux S; Massicotte MH; Huot Daneault A; Brazeau-Lamontagne L; Dufresne J
Bone; 2019 Mar; 120():482-486. PubMed ID: 30572144
[TBL] [Abstract][Full Text] [Related]
2. Hypercalcemia upon denosumab withdrawal in primary hyperparathyroidism: a case report and literature review.
Camponovo C; Aubry-Rozier B; Lamy O; Gonzalez Rodriguez E
Osteoporos Int; 2020 Dec; 31(12):2485-2491. PubMed ID: 33057735
[TBL] [Abstract][Full Text] [Related]
3. Elevated levels of circulating fibroblast growth factor 23 with hypercalcemia following discontinuation of denosumab.
Uchida T; Yamaguchi H; Kushima C; Yonekawa T; Nakazato M
Endocr J; 2020 Jan; 67(1):31-35. PubMed ID: 31527321
[TBL] [Abstract][Full Text] [Related]
4. Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL.
Kostenuik PJ; Nguyen HQ; McCabe J; Warmington KS; Kurahara C; Sun N; Chen C; Li L; Cattley RC; Van G; Scully S; Elliott R; Grisanti M; Morony S; Tan HL; Asuncion F; Li X; Ominsky MS; Stolina M; Dwyer D; Dougall WC; Hawkins N; Boyle WJ; Simonet WS; Sullivan JK
J Bone Miner Res; 2009 Feb; 24(2):182-95. PubMed ID: 19016581
[TBL] [Abstract][Full Text] [Related]
5. Rebound hypercalcemia post-denosumab cessation in metastatic breast cancer.
Wang R; Renouf DA
Osteoporos Int; 2022 Jul; 33(7):1625-1629. PubMed ID: 35286436
[TBL] [Abstract][Full Text] [Related]
6. Denosumab: an Emerging Therapy in Pediatric Bone Disorders.
Boyce AM
Curr Osteoporos Rep; 2017 Aug; 15(4):283-292. PubMed ID: 28643220
[TBL] [Abstract][Full Text] [Related]
7. Long-term follow up after denosumab treatment for osteoporosis - rebound associated with hypercalcemia, parathyroid hyperplasia, severe bone mineral density loss, and multiple fractures: a case report.
Maugars Y; Guillot P; Glémarec J; Berthelot JM; Le Goff B; Darrieutort-Laffite C
J Med Case Rep; 2020 Aug; 14(1):130. PubMed ID: 32792004
[TBL] [Abstract][Full Text] [Related]
8. Denosumab for treatment of hypercalcemia of malignancy.
Hu MI; Glezerman IG; Leboulleux S; Insogna K; Gucalp R; Misiorowski W; Yu B; Zorsky P; Tosi D; Bessudo A; Jaccard A; Tonini G; Ying W; Braun A; Jain RK
J Clin Endocrinol Metab; 2014 Sep; 99(9):3144-52. PubMed ID: 24915117
[TBL] [Abstract][Full Text] [Related]
9. Denosumab treatment for fibrous dysplasia.
Boyce AM; Chong WH; Yao J; Gafni RI; Kelly MH; Chamberlain CE; Bassim C; Cherman N; Ellsworth M; Kasa-Vubu JZ; Farley FA; Molinolo AA; Bhattacharyya N; Collins MT
J Bone Miner Res; 2012 Jul; 27(7):1462-70. PubMed ID: 22431375
[TBL] [Abstract][Full Text] [Related]
10. Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data.
Dempster DW; Lambing CL; Kostenuik PJ; Grauer A
Clin Ther; 2012 Mar; 34(3):521-36. PubMed ID: 22440513
[TBL] [Abstract][Full Text] [Related]
11. Hypercalcemia after discontinuation of long-term denosumab treatment.
Koldkjær Sølling AS; Harsløf T; Kaal A; Rejnmark L; Langdahl B
Osteoporos Int; 2016 Jul; 27(7):2383-2386. PubMed ID: 27098536
[TBL] [Abstract][Full Text] [Related]
12. RANKL as a target for the treatment of osteoporosis.
Matsumoto T; Endo I
J Bone Miner Metab; 2021 Jan; 39(1):91-105. PubMed ID: 33057808
[TBL] [Abstract][Full Text] [Related]
13. [Anti-RANKL antibody].
Omiya T; Tanaka S
Nihon Rinsho; 2015 Oct; 73(10):1690-5. PubMed ID: 26529931
[TBL] [Abstract][Full Text] [Related]
14. Treatment of chronic hypercalcemia.
Camozzi V; Luisetto G; Basso SM; Cappelletti P; Tozzoli R; Lumachi F
Med Chem; 2012 Jul; 8(4):556-63. PubMed ID: 22571196
[TBL] [Abstract][Full Text] [Related]
15. Severe hypercalcemia following denosumab treatment in a juvenile patient.
Setsu N; Kobayashi E; Asano N; Yasui N; Kawamoto H; Kawai A; Horiuchi K
J Bone Miner Metab; 2016 Jan; 34(1):118-22. PubMed ID: 26056018
[TBL] [Abstract][Full Text] [Related]
16. Malignant hypercalcemia.
Basso U; Maruzzo M; Roma A; Camozzi V; Luisetto G; Lumachi F
Curr Med Chem; 2011; 18(23):3462-7. PubMed ID: 21756237
[TBL] [Abstract][Full Text] [Related]
17. First use of the RANKL antibody denosumab in osteogenesis imperfecta type VI.
Semler O; Netzer C; Hoyer-Kuhn H; Becker J; Eysel P; Schoenau E
J Musculoskelet Neuronal Interact; 2012 Sep; 12(3):183-8. PubMed ID: 22947550
[TBL] [Abstract][Full Text] [Related]
18. A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer.
Body JJ; Facon T; Coleman RE; Lipton A; Geurs F; Fan M; Holloway D; Peterson MC; Bekker PJ
Clin Cancer Res; 2006 Feb; 12(4):1221-8. PubMed ID: 16489077
[TBL] [Abstract][Full Text] [Related]
19. Denosumab for the treatment of cancer therapy-induced bone loss and prevention of skeletal-related events in patients with solid tumors.
Lipton A; Balakumaran A
Expert Rev Clin Pharmacol; 2012 Jul; 5(4):359-71. PubMed ID: 22943116
[TBL] [Abstract][Full Text] [Related]
20. Osteonecrosis of the Jaw and Rebound Hypercalcemia in Young People Treated With Denosumab for Giant Cell Tumor of Bone.
Uday S; Gaston CL; Rogers L; Parry M; Joffe J; Pearson J; Sutton D; Grimer R; Högler W
J Clin Endocrinol Metab; 2018 Feb; 103(2):596-603. PubMed ID: 29211870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
